Retinal Disease
Cases & Conversations™: Real World Review of Treat and Extend Strategies for Neovascular Retinal Disease
This activity is supported by Regeneron Pharmaceuticals, Inc.
VIDEO: Molecular screening helpful to differentiate uveitis, inherited retinal dystrophies
BARCELONA, Spain — In this Healio Video Perspective from the Euretina congress, Bart Leroy, MD, PhD, speaks about the overlapping features of uveitis and inherited retinal dystrophies.
Inherited Retinal Diseases: Navigating the Future of Diagnostics and Emerging Therapies
This activity is supported by an educational grant from Janssen Pharmaceuticals, Inc., administered by Janssen Scientific Affairs, LLC.
Innovations in eye care with Steven Schwartz, MD, and Sean Ianchulev, MD (Re-Release)
In this special throwback episode, John Hovanesian, MD, and Jim Mazzo revisit their discussions with Steven Schwartz, MD, and Sean Ianculev, MD, about innovations, treatments and entrepreneurship in eye care.
The Retina Radar With Dr. Arshad Khanani on CTS, nAMD, DME, and Sustained Delivery
This activity is supported by independent medical education grants from Regeneron Pharmaceuticals, Inc.; Genentech, a member of the Roche Group; AbbVie Inc.; Astellas; Apellis Pharmaceuticals, Inc.; Opthea; Alimera Sciences, Inc.; EyePoint Pharmaceuticals, Inc.; Neurotech Pharmaceuticals, Inc.; REGENXBIO Inc.; and Ocular Therapeutix, Inc.
Do you expect to use more biosimilars in the future?
Undoubtedly, cost can be a barrier to optimal anti-VEGF treatment in the United States and around the world.
Q&A: Susvimo delivers immediate durability after implantation in wet AMD
Nearly 2 years after it voluntarily recalled Susvimo, Genentech recently announced plans to reintroduce the implant.
AREDS2 supplement slows expansion of geographic atrophy, even in late-stage AMD
Taking a daily supplement with antioxidant vitamins and minerals may slow the progression of late-stage dry age-related macular degeneration and could help maintain central vision in affected patients, according to researchers at NIH.
In Case You Missed...Mastering the Latest in Retinal Disease Management
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.
VIDEO: RevOpsis prepares for first-in-human trials of RO-104
PARK CITY, Utah — In this Healio Video Perspective from Clinical Trials at the Summit, Ramanath Bhandari, MD, FASRS, of RevOpsis Therapeutics discusses the development of RO-104 for the treatment of retinal disease.